Non-Interventional Study of Xeloda (Capecitabine) in Patients With Gastric Cancer

Roche

Status: Completed

Conditions: Gastric Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT02274376

ML21556

Details and patient eligibility

About

This observational study will collect prospective data on the safety and tolerability of Xeloda in patients with advanced gastric cancer from every day clinical practice. Documentation of treatment for each patient is to continue until the end of treatment per oncologist's assessment.

Enrollment: 223 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients aged >/=18 years, with metastatic gastric cancer who are available for prospective documentation of their treatment (first-line chemotherapy)
• Informed consent

Exclusion criteria

• Contraindications to Xeloda per the Summary of Product Characteristics (SmPC)

Trial design

223 participants in 1 patient group

Cohort